drugset / Trial / NCT00998933

Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure

NCT00998933

Phase 1 Completed 24 enrolled Solvay Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To further characterize the transfer potential of marketed testosterone gel and new 1.62% formulation.

Timeline

Start
2009-10
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Small molecule 5 g Topical

Indications